While TPV/eGFP and TPV/∆66R/m-IL-2/mCherry demonstrated a trend of regressed tumor volume over the course of the study, both recombinants failed to reach statistical significance (Figure 1A,B). The gene discussed is IL2; the disease is neoplasm.